Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 5 od 7  
Back povratak na rezultate
2018, vol. 146, br. 11-12, str. 641-645
Zastupljenost antitela velikog kašlja kod odraslog stanovništva
aInstitut za javno zdravlje Vojvodine, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet
bInstitut za javno zdravlje Vojvodine, Novi Sad

e-adresavladimir.petrovic@mf.uns.ac.rs
Sažetak
Uvod/Cilj Seroepidemiološke studije su od presudnog značaja za bolje razumevanje epidemiologije pertusisa u populaciji. Cilj rada bio je da se proceni seroprevalencija antitela na infekciju Bordetella pertussis (anti-PT IgG) kod odraslog stanovništva i utvrde razlike u odnosu na uzrast i pol. Metode rada Studija preseka je sprovedena kod 468 zdravih odraslih osoba, starijih od 20 godina, raspoređenih u sedam uzrasnih grupa. Najmlađi učesnici studije dobili su poslednju dozu vakcine pre najmanje 18 godina. Pozitivni rezultati koncentracija anti-PT IgG smatrani su posledicama prirodne infekcije ili reinfekcije. Za određivanje nivoa anti-PT IgG korišćen je komercijalni ELISA kit (EuroimmunR, Nemačka) sa četiri kalibratora: 5 IJ/ml, 25 IJ/ml, 100 IJ/ml i 200 IJ/ml. Rezultati Kod većine ispitanika (53,8%) registrovan je nivo anti-PT IgG u rasponu 5-62,5 IJ/ml. Statistički značajno veći procenat žena imao je visoke koncentracije anti-PT IgG (62,5-125 IJ/ml) u odnosu na muškarce (5,4% naspram 0,4%, p = 0,002). Najviše vrednosti anti-PT IgG registrovane su kod ispitanika uzrasta 20-24 godine (17,5 ( 22,2) i uzrasta ≥ 60 godina (15 ( 29,4). Procenat anti-PT IgG koncentracija ≥ 62,5 IJ/ml bio je najviši kod osoba uzrasta ≥ 60 godina (6,6%) i u uzrastu 20-24 godine (5%). Zaključak Ograničeno trajanje vakcinalnog imuniteta i sledstvena pojava infekcija ili reinfekcija omogućavaju održavanje velikog kašlja među odraslom populacijom i predstavljaju rezervoare zaraze za prenošenje infekcije na posebno osetljive osobe.
Reference
*** (2010) Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec, 85(40):385-400
*** (2006-2015) Pravilnik o imunizaciji i načinu zaštite lekovima. Službeni glasnik Republike Srbije, broj 11/2006, 25/2013, 63/2013, 99/2013, 118/2013, 65/2014 i 32/2015
Blain, A.E., Lewis, M., Banerjee, E., Kudish, K., Liko, J., McGuire, S., Selvage, D., Watt, J., Martin, S.W., Skoff, T.H. (2016) An Assessment of the Cocooning Strategy for Preventing Infant Pertussis-United States, 2011. Clinical Infectious Diseases, 63(suppl 4): S221-S226
Cagney, M., Macintyre, C.R., Mcintyre, P., Puech, M., Giammanco, A. (2006) The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiology and Infection, 134(06): 1208
Campbell, P., McIntyre, P., Quinn, H., Hueston, L., Gilbert, G.L., McVernon, J. (2012) Increased Population Prevalence of Low Pertussis Toxin Antibody Levels in Young Children Preceding a Record Pertussis Epidemic in Australia. PLoS One, 7(4): e35874
Demelker, H., Versteegh, F., Schellekens, J., Teunis, P., Kretzschmar, M. (2006) The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. Journal of Infection, 53(2): 106-113
Edwards, K., Decker, M.D. (2013) Whooping cough vaccine. u: Plotkin S.A.; Orenstein W.A.; Offit P.A. [ur.] Vaccines, Philadelphia: Elsevier, 6th ed. p. 447-92
Fedele, G., Stefanelli, P. (2017) Pertussis in infants and the resurgence of a vaccine preventable disease: what to do?. Ann Ist Super Sanita, 53(2): 100-3
Giammanco, A., Chiarini, A., Maple, P., Andrews, N., Pebody, R., Gay, N., Ölander, R., Fivet-Groyne, F., Baron, S., Tischer, A., Swidsinski, S., Schellekens, J., Reizenstein, E. (2003) European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine, 22(1): 112-120
Guiso, N., Berbers, G., Fry, N.K., He, Q., Riffelmann, M., Wirsing, von K.C.H. (2011) What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. European Journal of Clinical Microbiology & Infectious Diseases, 30(3): 307-312
Huygen, K., Rodeghiero, C., Govaerts, D., Leroux-Roels, I., Melin, P., Reynders, M., van Der, M.S., van den Wijngaert, S., Pierard, D. (2014) Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012. Epidemiology and Infection, 142(04): 724-728
Institute of Public Health of Vojvodina (2016) Communicable diseases in Vojvodina, 2015: Annual report. Novi Sad, p. 112-6
Jardine, A., Conaty, S.J., Lowbridge, C., Staff, M., Vally, H. (2010) Who gives pertussis to infants?, Source of infection for laboratory confirmed cases less than 12 months of age during an epidemic, Sydney, 2009. Commun Dis Intell Q Rep., 34(2): 116-21
Jõgi, P., Oona, M., Toompere, K., Leedo, S., Epstein, J., Lutsar, I. (2014) Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia. Vaccine, 32(41): 5311-5315
Jõgi, P., Oona, M., Toompere, K., Lutsar, I. (2015) Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study. Vaccine, 33(38): 4756-4761
Kilgore, P.E., Salim, A.M., Zervos, M.J., Schmitt, H. (2016) Pertussis: Microbiology, Disease, Treatment, and Prevention. Clinical Microbiology Reviews, 29(3): 449-486
Krishnaswamy, S., Wallace, E.M., Cheng, A.C., Buttery, J., Giles, M.L. (2017) Protecting newborns from pertussis: The role of partner vaccination in the era of maternal immunization. European Journal of Obstetrics & Gynecology and Reproductive Biology, 216: 159-163
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., i dr. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859): 2095-128
Miyashita, N., Akaike, H., Teranishi, H., Kawai, Y., Ouchi, K., Kato, T., Hayashi, T., Okimoto, N. (2013) Diagnostic value of symptoms and laboratory data for pertussis in adolescent and adult patients. BMC Infectious Diseases, 13(1):
Petrović, V., Đurić, P., Stefanović, S. (2006) Epidemiološke karakteristike pertussisa u Vojvodini. Medicinski pregled, vol. 59, br. 1-2, str. 19-23
Plotkin, S.A. (2014) The Pertussis Problem. Clinical Infectious Diseases, 58(6): 830-833
Quinn, H.E., Mcintyre, P.B., Backhouse, J.L., Gidding, H.F., Brotherton, J., Gilbert, G.L. (2010) The utility of seroepidemiology for tracking trends in pertussis infection. Epidemiology and Infection, 138(03): 426
Rønn, P.F., Dalby, T., Simonsen, J., Jørgensen, C.S., Linneberg, A., Krogfelt, K.A. (2014) Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark. Epidemiology and Infection, 142(04): 729-737
Sigera, S., Perera, J., Rasarathinam, J., Samaranayake, D., Ediriweera, D. (2016) Seroprevalence of Bordetella pertussis specific Immunoglobulin G antibody levels among asymptomatic individuals aged 4 to 24 years: a descriptive cross sectional study from Sri Lanka. BMC Infectious Diseases, 16(1):
Skoff, T.H., Kenyon, C., Cocoros, N., Liko, J., Miller, L., Kudish, K., Baumbach, J., Zansky, S., Faulkner, A., Martin, S.W. (2015) Sources of Infant Pertussis Infection in the United States. Pediatrics, 136(4): 635-641
Sočan, M., Prosenc, K., Vegnuti, M. (2006) Seroprevalenz von IgG Antikörpern gegen Pertussis-Toxin in der slowenischen Population. Wiener klinische Wochenschrift, 118(11-12): 336-340
Torzsa, P., Devadiga, R., Tafalla, M. (2017) Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study. BMC Infectious Diseases, 17(1):
Wiley, K.E., Zuo, Y., Macartney, K.K., McIntyre, P.B. (2013) Sources of pertussis infection in young infants: A review of key evidence informing targeting of the cocoon strategy. Vaccine, 31(4): 618-625
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/SARH171109203P
objavljen u SCIndeksu: 18.01.2019.

Povezani članci

Srps arh celokup lekarstvo (2018)
Veliki kašalj kod dece mlađe od deset godina
Ristić Mioljub, i dr.

Srps arh celokup lekarstvo (2019)
Sezonska distribucija velikog kašlja
Ristić Mioljub, i dr.

Srps arh celokup lekarstvo (2019)
Evaluacija dijagnostičke vrednosti nove definicije slučaja velikog kašlja - iskustva iz sentinelnog i hospitalnog nadzora nad velikim kašljem
Ristić Mioljub, i dr.

prikaži sve [6]